These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25707875)

  • 1. Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized Study.
    Hellemans R; Hazzan M; Durand D; Mourad G; Lang P; Kessler M; Charpentier B; Touchard G; Berthoux F; Merville P; Ouali N; Squifflet JP; Bayle F; Wissing KM; Noël C; Abramowicz D
    Am J Transplant; 2015 Jul; 15(7):1923-32. PubMed ID: 25707875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
    Saull HE; Enderby CY; Gonwa TA; Wadei HM
    Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients.
    Noël C; Abramowicz D; Durand D; Mourad G; Lang P; Kessler M; Charpentier B; Touchard G; Berthoux F; Merville P; Ouali N; Squifflet JP; Bayle F; Wissing KM; Hazzan M
    J Am Soc Nephrol; 2009 Jun; 20(6):1385-92. PubMed ID: 19470677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation.
    Alloway RR; Woodle ES; Abramowicz D; Segev DL; Castan R; Ilsley JN; Jeschke K; Somerville KT; Brennan DC
    Am J Transplant; 2019 Aug; 19(8):2252-2261. PubMed ID: 30838775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.
    Deeks ED; Keating GM
    Drugs; 2009 Jul; 69(11):1483-512. PubMed ID: 19634926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
    Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
    Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8years of follow-up.
    Ciancio G; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Ruiz P; Vianna R; Burke GW
    Transpl Immunol; 2017 Feb; 40():42-50. PubMed ID: 27888093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database.
    Jindal RM; Das NP; Neff RT; Hurst FP; Falta EM; Elster EA; Abbott KC
    Am J Nephrol; 2009; 29(6):501-8. PubMed ID: 19060477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
    N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
    Laftavi MR; Alnimri M; Weber-Shrikant E; Kohli R; Said M; Patel S; Pankewycz O
    Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin.
    Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Doares W; Kaczmorski S; Farney AC
    Expert Opin Biol Ther; 2014 Dec; 14(12):1723-30. PubMed ID: 25156622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation.
    Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Farney AC
    Transplant Proc; 2014; 46(6):1928-31. PubMed ID: 25131073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience.
    Huang HF; Zhou JY; Xie WQ; Wu JY; Deng H; Chen JH
    Int Urol Nephrol; 2016 Aug; 48(8):1363-1370. PubMed ID: 27170340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
    Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of rejection after basiliximab induction in sensitized kidney transplant recipients without pre-existing donor-specific antibodies - a retrospective study.
    Goumard A; Sautenet B; Bailly E; Miquelestorena-Standley E; Proust B; Longuet H; Binet L; Baron C; Halimi JM; Büchler M; Gatault P
    Transpl Int; 2019 Aug; 32(8):820-830. PubMed ID: 30903722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.